<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kura Oncology Inc — News on 6ix</title>
    <link>https://6ix.com/company/kura-oncology-inc</link>
    <description>Latest news and press releases for Kura Oncology Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 24 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/kura-oncology-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358efd78dffbe2df101711.webp</url>
      <title>Kura Oncology Inc</title>
      <link>https://6ix.com/company/kura-oncology-inc</link>
    </image>
    <item>
      <title>Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kyowa-kirin-and-kura-oncology-initiate-japanese-phase-2-registration-directed-trial-of-ziftomenib-in-rr-npm1-m-aml-1</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kyowa-kirin-and-kura-oncology-initiate-japanese-phase-2-registration-directed-trial-of-ziftomenib-in-rr-npm1-m-aml-1</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 GMT</pubDate>
      <description>– Regulatory Filing in Japan Planned Following Clinical Trial Completion –TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m A</description>
    </item>
    <item>
      <title>Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib</guid>
      <pubDate>Fri, 17 Apr 2026 10:00:00 GMT</pubDate>
      <description>Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off M</description>
    </item>
    <item>
      <title>Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-to-present-darlifarnib-plus-cabozantinib-data-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib-at-ikcs-europe-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-to-present-darlifarnib-plus-cabozantinib-data-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib-at-ikcs-europe-2026</guid>
      <pubDate>Thu, 09 Apr 2026 11:30:00 GMT</pubDate>
      <description>Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT</description>
    </item>
    <item>
      <title>Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-6</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-6</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety,</description>
    </item>
    <item>
      <title>Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.</description>
    </item>
    <item>
      <title>Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-inducement-grants-123000624</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-inducement-grants-123000624</guid>
      <pubDate>Fri, 06 Feb 2026 12:30:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 69,750 shares of common stock to four (4) new employees under the Company</description>
    </item>
    <item>
      <title>Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-highlights-recent-accomplishments-preliminary-komzifti-revenue-and</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-highlights-recent-accomplishments-preliminary-komzifti-revenue-and</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net</description>
    </item>
    <item>
      <title>Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-report-combination-data-komziftitm-ziftomenib</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-report-combination-data-komziftitm-ziftomenib</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS –</description>
    </item>
    <item>
      <title>Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-host-virtual-investor-event-discuss-data-presented-ash-2025-triplet</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-host-virtual-investor-event-discuss-data-presented-ash-2025-triplet</guid>
      <pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
      <description>Event Scheduled for December 8, 2025 at 12:30 PM ET SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical</description>
    </item>
    <item>
      <title>First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/first-us-commercial-sale-komziftitm-triggers-135-million-milestone-payment-kura</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/first-us-commercial-sale-komziftitm-triggers-135-million-milestone-payment-kura</guid>
      <pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of</description>
    </item>
    <item>
      <title>KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/komziftitm-ziftomenib-added-national-comprehensive-cancer-networkr-nccn-guidelines</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/komziftitm-ziftomenib-added-national-comprehensive-cancer-networkr-nccn-guidelines</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States SAN DIEGO</description>
    </item>
    <item>
      <title>Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm-ziftomenib-first-and</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm-ziftomenib-first-and</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by</description>
    </item>
    <item>
      <title>Kura Oncology to Participate in Upcoming Investor Conference</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-participate-upcoming-investor-conference-2025-11-12</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-participate-upcoming-investor-conference-2025-11-12</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise</description>
    </item>
    <item>
      <title>Kura Oncology Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-third-quarter-2025-financial-results-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-reports-third-quarter-2025-financial-results-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –</description>
    </item>
    <item>
      <title>Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-announce-presentations-ziftomenib-ven-aza-combination</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-announce-presentations-ziftomenib-ven-aza-combination</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and</description>
    </item>
    <item>
      <title>Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-receives-second-30-million-development-milestone-payment-aml-menin</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-receives-second-30-million-development-milestone-payment-aml-menin</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>Kura Oncology to Report Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-report-third-quarter-2025-financial-results-2025-10-28</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-report-third-quarter-2025-financial-results-2025-10-28</guid>
      <pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise</description>
    </item>
    <item>
      <title>Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-receives-30-million-development-milestone-payment-ziftomenib-aml</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-receives-30-million-development-milestone-payment-ziftomenib-aml</guid>
      <pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
      <description>- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.</description>
    </item>
    <item>
      <title>Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-announces-preliminary-data-its-farnesyl-transferase-inhibitor-fti</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-announces-preliminary-data-its-farnesyl-transferase-inhibitor-fti</guid>
      <pubDate>Sat, 18 Oct 2025 04:00:00 GMT</pubDate>
      <description>FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support</description>
    </item>
    <item>
      <title>Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)</title>
      <link>https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-launch-clinical-trial-evaluating-dual-inhibition-npm1</link>
      <guid isPermaLink="true">https://6ix.com/company/kura-oncology-inc/news/kura-oncology-and-kyowa-kirin-launch-clinical-trial-evaluating-dual-inhibition-npm1</guid>
      <pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
      <description>– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3</description>
    </item>
  </channel>
</rss>